

# Mark W Hull

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6814078/mark-w-hull-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44  
papers

823  
citations

15  
h-index

28  
g-index

50  
ext. papers

998  
ext. citations

4.6  
avg, IF

4.07  
L-index

#	Paper	IF	Citations
44	Depressive symptoms are no longer a barrier to HCV treatment initiation in the HIV/HCV co-infected population in Canada. <i>Antiviral Therapy</i> , <b>2022</b> , 27, 135965352110676	1.6	
43	Community-Based Participatory Approaches to Knowledge Translation: HIV Prevention Case Study of the Investigaytors Program. <i>Archives of Sexual Behavior</i> , <b>2021</b> , 50, 105-117	3.5	3
42	Interest in Hypothetical Preexposure Prophylaxis Against Herpes Simplex Virus: A Cross-Sectional Survey. <i>Sexually Transmitted Diseases</i> , <b>2021</b> , 48, e105-e108	2.4	
41	Routine HIV testing in acute care hospitals: Changing practice to curb a local HIV epidemic in Vancouver, BC. <i>Preventive Medicine</i> , <b>2020</b> , 137, 106132	4.3	2
40	Community awareness of, use of and attitudes towards HIV pre-exposure prophylaxis (PrEP) among men who have sex with men in Vancouver, Canada: preparing health promotion for a publicly funded PrEP program. <i>Sexual Health</i> , <b>2019</b> , 16, 180-186	2	7
39	Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP. <i>Antiviral Therapy</i> , <b>2019</b> , 24, 211-220	1.6	0
38	HIV, schizophrenia, and all-cause mortality: A population-based cohort study of individuals accessing universal medical care from 1998 to 2012 in British Columbia, Canada. <i>Schizophrenia Research</i> , <b>2019</b> , 209, 198-205	3.6	6
37	The PrEP You Want: A Web-Based Survey of Online Cross-Border Shopping for HIV Prophylaxis Medications. <i>Journal of Medical Internet Research</i> , <b>2019</b> , 21, e12076	7.6	2
36	Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2019</b> , 82, 71-80	3.1	10
35	Trends in cause-specific mortality in HIV-hepatitis C coinfection following hepatitis C treatment scale-up. <i>Aids</i> , <b>2019</b> , 33, 1013-1022	3.5	11
34	Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting. <i>Liver International</i> , <b>2019</b> , 39, 1400-1407	7.9	35
33	Trends in discharges from the HIV/AIDS ward at a tertiary Canadian Hospital from 2005 to 2014. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2018</b> , 30, 1099-1106	2.2	5
32	Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients. <i>Aids</i> , <b>2018</b> , 32, 751-759	3.5	7
31	Cohort profile: the Comparative Outcomes And Service Utilization Trends (COAST) Study among people living with and without HIV in British Columbia, Canada. <i>BMJ Open</i> , <b>2018</b> , 8, e019115	3	12
30	Trends in Awareness and Use of HIV PrEP Among Gay, Bisexual, and Other Men who have Sex with Men in Vancouver, Canada 2012-2016. <i>AIDS and Behavior</i> , <b>2018</b> , 22, 3550-3565	4.3	29
29	Factors Associated with Mood Disorder Diagnosis Among a Population Based Cohort of Men and Women Living With and Without HIV in British Columbia Between 1998 and 2012. <i>AIDS and Behavior</i> , <b>2018</b> , 22, 1530-1540	4.3	6
28	Real-world impact of direct acting antiviral therapy on health-related quality of life in HIV/Hepatitis C co-infected individuals. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 1507-1514	3.4	15

27	Feasibility of vitamin D supplementation interventions to mitigate HIV pre-exposure prophylaxis-related bone mineral density loss: a cross-sectional survey. <i>Patient Preference and Adherence</i> , <b>2018</b> , 12, 2197-2204	2.4	2
26	Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada. <i>Journal of the International AIDS Society</i> , <b>2018</b> , 21, e25197	5.4	9
25	Effect of opioid-substitution therapy and mental health counseling on HIV risk among hepatitis C-infected individuals. <i>Clinical Epidemiology</i> , <b>2018</b> , 10, 1127-1145	5.9	6
24	Changes in mortality rates and causes of death in a population-based cohort of persons living with and without HIV from 1996 to 2012. <i>BMC Infectious Diseases</i> , <b>2017</b> , 17, 174	4	64
23	Health-adjusted life expectancy in HIV-positive and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study. <i>Lancet HIV,the</i> , <b>2017</b> , 4, e270-e276	7.8	34
22	Knowledge of hepatitis C and treatment willingness amongst people who inject drugs in an era of direct acting antivirals. <i>International Journal of Drug Policy</i> , <b>2017</b> , 47, 137-143	5.5	17
21	Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. <i>Cmaj</i> , <b>2017</b> , 189, E1448-E1458	3.5	101
20	Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada. <i>Journal of the International AIDS Society</i> , <b>2017</b> , 20, e25013	5.4	37
19	Achieving the 90-90-90 target: incentives for HIV testing. <i>Lancet Infectious Diseases, The</i> , <b>2016</b> , 16, 1215-1216	13.6	8
18	Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function. <i>Journal of the International AIDS Society</i> , <b>2016</b> , 19, 20995	5.4	3
17	Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients. <i>Current Infectious Disease Reports</i> , <b>2016</b> , 18, 22	3.9	13
16	Sexually-transmitted seronegative HCV infection in an HIV-positive post-liver transplant recipient. Case report and review of the literature. <i>Journal of Clinical Virology</i> , <b>2016</b> , 79, 51-53	14.5	
15	Retrospective cohort study of inappropriate piperacillin-tazobactam use for lower respiratory tract and skin and soft tissue infections: Opportunities for antimicrobial stewardship. <i>American Journal of Infection Control</i> , <b>2015</b> , 43, 946-50	3.8	5
14	Comparing the efficacy of efavirenz and boosted lopinavir using viremia copy-years. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 18617	5.4	6
13	Mucor velutinosus Central-Line-Associated Bloodstream Infection. <i>Clinical Microbiology Newsletter</i> , <b>2013</b> , 35, 176-177	1.1	2
12	HIV treatment as prevention: the key to an AIDS-free generation. <i>Journal of Food and Drug Analysis</i> , <b>2013</b> , 21, S95-S101	7	31
11	Variation between Canadian centres in the uptake of treatment for hepatitis C by patients coinfecting with HIV: a prospective cohort study. <i>CMAJ Open</i> , <b>2013</b> , 1, E106-14	2.5	12
10	Epidemic of lung cancer in patients with HIV infection. <i>Chest</i> , <b>2013</b> , 143, 305-314	5.3	61

9	Optimizing the engagement of care cascade: a critical step to maximize the impact of HIV treatment as prevention. <i>Current Opinion in HIV and AIDS</i> , <b>2012</b> , 7, 579-86	4.2	81
8	Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , <b>2012</b> , 26, 1789-94	3.5	16
7	Antiretroviral therapy: a key component of a comprehensive HIV prevention strategy. <i>Current HIV/AIDS Reports</i> , <b>2011</b> , 8, 85-93	5.9	19
6	Ritonavir-boosted protease inhibitors in HIV therapy. <i>Annals of Medicine</i> , <b>2011</b> , 43, 375-88	1.5	82
5	Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. <i>AIDS</i> 2009; 23: 2289-300.	4	1
4	Incorporation of ANTI-HHV-8 Agents as Targeted Therapy for the Treatment of HIV-Associated Primary Effusion Lymphoma.. <i>Blood</i> , <b>2009</b> , 114, 4768-4768	2.2	
3	Indigenous microflora and innate immunity of the head and neck. <i>Infectious Disease Clinics of North America</i> , <b>2007</b> , 21, 265-82, v	6.5	40
2	Clostridium difficile-associated colitis. <i>Canadian Family Physician</i> , <b>2004</b> , 50, 1536-40, 1543-5	0.9	17
1	Public health morality, sex, and COVID-19: sexual minority men's HIV pre-exposure prophylaxis (PrEP) decision-making during Ontario's first COVID-19 lockdown. <i>Critical Public Health</i> , 1-11	2.6	5